文献速递糖尿病

抑制1型糖尿病候选基因PTPN2加重TNF-α诱导的人β细胞功能障碍和死亡

Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.
PubMed 文献 · Diabetologia · 2023-03-29

研究评估TNF-α与I型干扰素在人生β细胞中与1型糖尿病候选基因PTPN2的交互作用。在EndoC-βH1细胞、分散人胰岛或iPSC来源胰岛样细胞中沉默PTPN2,使IFN-α和/或TNF-α诱导的细胞毒性增加20-50%,且两种细胞因子间无增强效应。沉默JNK1或BIM可消除上述促凋亡效应。

要点

  • PTPN2沉默使β细胞对IFN-α和/或TNF-α诱导的细胞毒性增加20-50%,取决于所用人类细胞模型。
  • 沉默JNK1或BIM可消除PTPN2抑制后IFN-α、TNF-α或两者联合的促凋亡效应。
  • PTPN2沉默增加TNF-α诱导的JNK1和BIM磷酸化,JNK3为β细胞抵抗IFN-α细胞毒性所必需。

核心结论

  • PTPN2是TNF-α在人类β细胞中有害效应的关键调节因子。
  • 携带风险相关PTPN2多态性的1型糖尿病患者可能特别受益于抑制TNF-α的疗法。

研究设计与样本

  • 研究使用EndoC-βH1细胞、分散人胰岛或诱导多能干细胞(iPSC)来源胰岛样细胞,转染靶向不同基因的siRNA(siCTRL、siPTPN2、siJNK1、siJNK3或siBIM),并用IFN-α(2000 U/ml)或TNF-α(1000 U/ml)处理48小时。

主要发现

  • PTPN2沉默使β细胞对IFN-α和/或TNF-α诱导的细胞毒性增加20-50%,取决于所用人类细胞模型;细胞因子间无增强效应。
  • 沉默JNK1或BIM可消除PTPN2抑制后IFN-α、TNF-α或两者联合的促凋亡效应。
  • PTPN2沉默增加TNF-α诱导的JNK1和BIM磷酸化。
  • JNK3为β细胞抵抗IFN-α细胞毒性所必需。

临床怎么用

  • 作者认为,携带风险相关PTPN2多态性的1型糖尿病患者可能特别受益于抑制TNF-α的疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: TNF-α plays a role in pancreatic beta cell loss in type 1 diabetes mellitus. In clinical interventions, TNF-α inhibition preserves C-peptide levels in early type 1 diabetes. In this study we evaluated the crosstalk of TNF-α, as compared with type I IFNs, with the type 1 diabetes candidate gene PTPN2 (encoding protein tyrosine phosphatase non-receptor type 2 [PTPN2]) in human beta cells. METHODS: EndoC-βH1 cells, dispersed human pancreatic islets or induced pluripotent stem cell (iPSC)-derived islet-like cells were transfected with siRNAs targeting various genes (siCTRL, siPTPN2, siJNK1, siJNK3 or siBIM). Cells were treated for 48 h with IFN-α (2000 U/ml) or TNF-α (1000 U/ml). Cell death was evaluated using Hoechst 33342 and propidium iodide staining. mRNA levels were assessed by quantitative reverse transcription PCR (qRT-PCR) and protein expression by immunoblot. RESULTS: PTPN2 silencing sensitised beta cells to cytotoxicity induced by IFN-α and/or TNF-α by 20-50%, depending on the human cell model utilised; there was no potentiation between the cytokines. We silenced c-Jun N-terminal kinase (JNK)1 or Bcl-2-like protein 2 (BIM), and this abolished the proapoptotic effects of IFN-α, TNF-α or the combination of both after PTPN2 inhibition. We further observed that PTPN2 silencing increased TNF-α-induced JNK1 and BIM phosphorylation and that JNK3 is necessary for beta cell resistance to IFN-α cytotoxicity. CONCLUSIONS/INTERPRETATION: We show that the type 1 diabetes candidate gene PTPN2 is a key regulator of the deleterious effects of TNF-α in human beta cells. It is conceivable that people with type 1 diabetes carrying risk-associated PTPN2 polymorphisms may particularly benefit from therapies inhibiting TNF-α.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Roca-Rivada A, Marín-Cañas S, Colli ML, et al. Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death. Diabetologia. 2023. PMID: 36988639. doi:10.1007/s00125-023-05908-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。